Company intelligence / Profile preview

Armune BioScience

Kalamazoo, Michigan, United States
Ownership
Private
Development stage
Other
01

Overview

Armune BioScience developed and commercialized diagnostic and prognostic tests for prostate, lung, and breast cancers based on detecting auto-antibody immune responses. Their lead test enabled earlier and more accurate cancer detection compared to competitors. The company was acquired by Exact Sciences.

Therapeutic areas
Oncology
Modalities
Diagnostic testProtein signature-based diagnosticAuto-antibody detection
Industry
Protein Biomarker Diagnostics
02

Partnerships

University of Michigan (technology license)

Beyond the preview

Go deeper on Armune BioScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Armune BioScience.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call